insights_auto
Zašto je KYNB pao 2,26%?
Istražite detaljnijechevron_right
KYNB:NASDAQ
Kyntra Bio Inc
6,50 USD
arrow_downward
−2,26%(−0,15) 1D
1. lis, 16:00:00 GMT -4 · USD
search
Svi simboli
| Simbol | Cijena | Promjena | Postotna promjena |
|---|
insights_autoGeneriranje najvažnijih uvida za KYNB...
Otvori
6,64 USD
Najviša
6,84 USD
Najniža
6,49 USD
Trž. kap.
26,32 mil.
Prosj. kol.
25,04 tis.
Količina
1,00
P/E omjer
0,14
52-tjed. najviša
9,70 USD
52-tjed. najniža
6,32 USD
EPS
45,30 USD
Beta
1,06
Dionice u optjecaju
4,05 mil.
Broj djelatnika
34
Otvori
6,64 USD
Najviša
6,84 USD
Najniža
6,49 USD
Trž. kap.
26,32 mil.
Prosj. kol.
25,04 tis.
Količina
1,00
P/E omjer
0,14
52-tjed. najviša
9,70 USD
52-tjed. najniža
6,32 USD
EPS
45,30 USD
Beta
1,06
Dionice u optjecaju
4,05 mil.
Broj djelatnika
34
Vijesti
Iz web-izvora i od partnera za vijesti
TipRanks
·
prije 22 sata
Kyntra Bio appoints new independent director, updates governance
Stock Titan
·
prije 23 sata
A director leaves after nearly eight years as Kyntra Bio adds a new board member
Profil
Kyntra Bio, Inc. is a biopharmaceutical company headquartered in San Francisco, California. Once regarded as a promising developer of innovative therapies for anemia and fibrotic diseases, with a market capitalization of roughly $4 billion in 2018–19, the company's value collapsed following late-stage trial failures, regulatory setbacks, and a data manipulation scandal. By 2026, Kyntra was mainly reduced to a single early-stage oncology drug candidate.
On January 8, 2026, FibroGen changed its name to Kyntra Bio and ticker symbol to KYNB. Wikipedia
Kyntra Bio Inc – informacije
Glavni izvršni direktor-
Zaposlenici34
Osnovano1. sij 1993.
SjedišteSan Francisco, Kalifornija, Sjedinjene Američke Države
Sektor-
Web-lokacijakyntrabio.com